Barbara Birkaya

Dr. Barbara Birkaya


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
BBBarbara Birkaya
Barbara Birkaya
ABAhana Byne
Ahana Byne
SISumaiya Irfan
Sumaiya Irfan
JGJoseph Gallagher
Joseph Gallagher
DGDominic Granato
Dominic Granato
ALAlessandra Luchini
Alessandra Luchini
The cause of chronic neurological effects associated with Lyme disease (LD) remains unclear. We propose that bacterial extracellular vesicles (BEVs) released by Borrelia burgdorferi, the causative agent of LD, exacerbate spirochete-induced damage and serve as a persistent source of antigenic stimulation. We showed that, over a 10-day period, in vitro cultures of B. burgdorferi B31 produced 38,000 BEVs per spirochete with a distinctive double-membrane structure and median diameter of 143.3 nm. BEVs contained known immunogenic and immunomodulatory molecules such as peptidoglycan, p66, flagellar filament protein (FlaB), basic membrane proteins A/B/D, BdrV, GroEL, CRASP-1, ErpA8, glycerophosphodiester phosphodiesterase, p37, OMS28, p13, OspA/B/C, VlsE, and outer membrane glycolipids (e.g., cholesteryl 6-O acyl beta D galactopyranoside). Chromosome-encoded 16S ribosomal RNA and cp32 plasmid-encoded OspE and terminase genes were also detected in the BEVs. Of the 45 Borrelia proteins identified in the urine of a C3H/HeJ murine model of Lyme disease, 14 were associated with BEVs. In human urine samples, 31 of 289 spirochete proteins detected in patients with either acute Lyme disease or persistent borreliosis post-treatment symptoms, including p66 and FlaB, were also BEV-associated. BEV treatment of HMC3 human microglial cells reduced phagocytic activity and triggered aberrant activation of inflammatory and immunometabolic pathways, including upregulation of interferon-alpha (IFN-α), aconitate decarboxylase 1 (Acod1), and Toll-like receptor 2 (TLR2) gene expression. BEVs also induced NRF2 nuclear translocation. In conclusion, these findings support that BEVs can amplify spirochete-induced damage and act as antigenic debris, driving dampened phagocytic activity and dysregulated inflammation, with implications for diagnostics and therapeutics targeting vesicle-mediated pathology.

7 July 2026
Verified
Book Chapter
Open access
PDF file
SDSindhu Datla
Sindhu Datla
BBBarbara Birkaya
Barbara Birkaya
ALAlessandra Luchini
Alessandra Luchini
Lyme disease is caused by Borrelia spirochetes and transmitted by Ixodid ticks. Laboratory diagnosis is challenging due to low and transient spirochetemia and an atypical host immune response over time. This chapter examines current and emerging diagnostic strategies for Lyme disease. We address indirect assays, such as ELISA and immunoblotting, and evaluate their performance and limitations across different stages of infection. Direct detection methods, particularly PCR-based assays, are also reviewed, with consideration of how sample type and analytical sensitivity influence their clinical application. Novel diagnostic approaches, including high-throughput, high-sensitivity assays to identify pathogen-derived molecules and host immune signatures, are reviewed. Throughout, we provide a comparative framework to evaluate these approaches by disease stage, specimen type, and clinical setting, and highlight key technological and infrastructure gaps that must be addressed to improve diagnostic accuracy across diverse populations worldwide.

6 August 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
FHFatema Hashemi
Fatema Hashemi
SCSilvia I Cachaco
Silvia I Cachaco
RPRocio Prisby
Rocio Prisby
WZWeidong Zhou
Weidong Zhou
GPGreg Petruncio
Greg Petruncio
LGLuisa Gregori
Luisa Gregori
Ensuring bacterial safety of blood transfusions remains a critical focus in medicine. We investigated a novel pathogen reduction technology utilizing nylon functionalized with synthetic dyes (nylon affinity networks) to capture and remove bacteria from plasma. In the initial screening process, we spiked phosphate buffer solution (PBS) and human plasma (1 mL each) with 10 or 100 colony forming units (cfu) of either Escherichia coli or Staphylococcus epidermidis, exposed the suspensions to affinity networks and assessed the extent of bacterial reduction using agar plate cultures as the assay output. Nineteen synthetic dyes were tested. Among these, Alcian Blue exhibited the best performance with both bacterial strains in both PBS and plasma. Next, bacterial suspensions of approximately 1 and 2 cfu/mL in 10 and 50 mL, respectively, were treated with Alcian Blue affinity networks in three sequential capture steps. This procedure resulted in complete bacterial depletion, as demonstrated by the lack of bacterial growth in the remaining fraction. The viability of the captured bacteria was confirmed by plating the post-treatment affinity networks on agar. Alcian Blue affinity networks captured and sequestered a few plasma proteins identified by liquid chromatography tandem mass spectrometry. These findings support the potential applicability of nylon affinity networks to enhance transfusion safety, although additional investigations are needed.